Evaluation of Pharmacokinetic Profile of GLP-1 Receptor Agonist Exenatide in Type 2 Diabetes Experimental Model

ABSTRACT

The study's objective was to evaluate Exenatide for treating Type 2 Diabetic Mellitus (T2DM) in an animal model. The safety profile and dose determination for the in vivo antidiabetic study were established through an acute toxicity study conducted by OECD guideline 425. The plasma levels of exenatide were studied using a pharmacokinetic model in rats. After Exenatide were given to the rats, their behavior, biochemical, and hematological characteristics were tested. Animals were administered Streptozotocin (STZ, 60 mg/mL, i/p) to induce diabetes. Blood glucose levels above 250 mg/dL were diagnostic of diabetes in animals. The drug was non-toxic in toxicity investigation. Results showed that administration of drug did not cause any significant change in behavioral, biochemical, or hematological markers. It was revealed that Exenatide significantly lowered blood glucose levels in diabetic animals. The results of the study indicated that Exenatide has the potential to be utilized as an alternative antidiabetic medicine against Type 2 Diabetes.

KEYWORDS

• Streptozotocin
• Toxicity
• Bioavailability
• Hematology
• Exenatide

Showing references and in-text citations exactly as published.

• DOI10.5530/ijpi.13.4.097Copy

RELATED ARTICLES

Matched on section and article type within this issue of IJPI.

• Article · VOLUME 13, ISSUE 4Formulation and Comparison of Topical Dosage Forms Containing P-Herbo Extract for Acne TherapyN. Raghavendra Naveen, Keerthiraj KS, Gaganashree G, Prajitha Biju, Annegowda H V, Sindhoor S M · pp. 747–753Original ArticleSame type: Article
• Article · VOLUME 13, ISSUE 4Development and Optimization of Candesartan Cilexetil Loaded Solid Lipid NanoparticlesKrithiga Venkatesan, Gouranga Dutta, Damodharan Narayanaswamy, Abimanyu Sugumaran · pp. 754–762Original ArticleSame type: Article
• Article · VOLUME 13, ISSUE 4Formulation and Evaluation of Propranolol Hydrochloride Sustained Release Matrix Tablets Using Different Grades of HPMC and MCCPiyali Khamkat, Vivek Barik, Bhakti Bhusan Barik, Aritra Chakraborty, Dipsikha Patra, Prasenjit Mondal, Snigdha Chatterjee · pp. 763–771Original ArticleSame type: Article
• Article · VOLUME 13, ISSUE 4Development of Albumin Coated Nanoparticulate Capecitabine SuppositoriesMythili Gopalakrishnan, Subramanian Somaskanthan · pp. 772–777Original ArticleSame type: Article